Checkpoint Therapeutics buy melinda
Startpreis
25.10.18
/
50%
2,25 €
Kursziel
31.10.18
2,53 €
Rendite (%)
17,27 %
Endpreis
31.10.18
2,63 €
Zusammenfassung
Diese Einschätzung wurde am 31.10.18 mit einem Endkurs von 2,63 € beendet. Mit einer Rendite von 17,27 % entwickelte sich die Einschätzung BUY ganz nach Plan. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - |
| iShares Core DAX® | 2,83 % | 1,24 % | 14,79 % | 17,65 % |
| iShares Nasdaq 100 | 2,92 % | 0,64 % | 40,29 % | 50,76 % |
| iShares Nikkei 225® | 2,01 % | -2,13 % | 19,86 % | 4,94 % |
| iShares S&P 500 | 2,26 % | 0,45 % | 30,09 % | 43,94 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Checkpoint Therapeutics diskutieren
SecteurRecherche biotechnologique et médicale
Operates as a biopharmaceutical company
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.
Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX).
It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP).
The company was founded on November 10, 2014 and is headquartered in New York, NY.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.
Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX).
It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP).
The company was founded on November 10, 2014 and is headquartered in New York, NY.
Nombre d'employés : 6 personnes.
(Zielkurs erreicht)
Beendete Einschätzungen von melinda zu Checkpoint Therapeutics
Checkpoint Therapeutics
Startkurs
Kursziel
Rendite (%)
5,84 €
13.10.17
13.10.17
8,12 €
19.12.17
19.12.17
-39,56 %
19.12.17
19.12.17
Checkpoint Therapeutics
Startkurs
Kursziel
Rendite (%)
6,47 €
13.10.17
13.10.17
9,00 €
19.12.17
19.12.17
-39,56 %
19.12.17
19.12.17